Protina Partners With Onconic Therapeutics on Next-Generation Cancer Drugs
AI drug developer Protina signed an MOU with Onconic Therapeutics to jointly develop next-generation cancer drugs, including molecular glue and antibody-drug conjugate (ADC) therapies.
Read the full articleYou might also wanna read
After TROP2 and HER2, Is B7-H3 the Next Big ADC Target?
Antibody-drug conjugates (ADCs) have become the hottest modality in oncology. The template was Enhertu, AstraZeneca and Daiichi Sankyo‘s HER
Molecular glue drugs show promise as breakthrough pancreatic cancer treatment, driving industry dealmaking
Revolution Medicines’ success in pancreatic cancer has ignited interest in a new type of medicine that’s sending dealmaking into overdrive.
mercurynews.com·1mo ago
Navigating the clinical progress of antibody-drug conjugates: Emerging opportunities and remaining challenges
Antibody-drug conjugates are among the fastest-growing anticancer therapies, delivering potent payloads directly to tumor cells with improve
AI accelerates search for cancer therapeutics in Korea
Artificial intelligence (AI) has helped SK Telecom and SK Biopharmaceuticals identify promising early compounds for a targeted cancer therap
Antibody-Drug Conjugates in Perioperative Treatment of Muscle-Invasive Bladder Cancer: Expert Perspectives
Are your treatment plans for MIBC current? Learn about the latest guidelines for perioperative antibody-drug conjugate (ADC)-based combinati
mdsc.pe·16d ago
South Korea’s AimedBio Invests in Inocras, Partners on WGS for Cancer Trials
The companies hope to find patients likely to respond to AimedBio’s antibody-drug conjugates.
Comments
Sign in to join the conversation.
No comments yet. Be the first.